Thursday, June 11, 2026

Intelligence Β· INN directory

Pharmaceutical Drugs

Regulatory status, brand names, and pipeline context for BD, medical affairs, and competitive intelligence teams.

Drugs indexed 4,797
Companies 1,769
Pipeline programs 20,548

Quick answer

NovaPharmaNews tracks 4,797 pharmaceutical drugs by INN (International Nonproprietary Name), with US FDA approval status, brand names, originators, routes of administration, and links to pipeline programs and patents. Search by generic name or browse A–Z for competitive intelligence and medical affairs reference.

Showing page 137 of 200 Β· By data quality, then INN

  1. solithromycin

    SOLITHROMYCIN TRISKEL EU SERVICES

    EMA: application withdrawn

    J01FA
  2. solriamfetol

    SUNOSI

    FDA: approved Β· EMA: approved Β· NMPA: clinical trials

    N06BA14
  3. somapacitan

    SOGROYA

    EMA: approved Β· NMPA: clinical trials

    H01AC07
  4. somatrogon

    NGENLA Pfizer Australia Pty Ltd

    EMA: approved Β· TGA: approved

    H01AC08
  5. sonidegib

    ODOMZO Lacuna Pharma Pty Ltd

    EMA: approved Β· TGA: approved

    L01XJ02
  6. sorafenib

    NEXAVAR Bayer Australia Ltd

    EMA: approved Β· TGA: approved Β· NMPA: clinical trials

    L01EX02
  7. sotatercept

    WINREVAIR

    EMA: approved Β· PMDA: approved

    C02KX06
  8. sotrovimab

    XEVUDY

    EMA: withdrawn Β· PMDA: approved

    J06BD05
  9. spesolimab

    SPEVIGO

    EMA: approved

    L04AC22
  10. spheroids of human autologous matrix-associated chondrocytes

    SPHEROX

    EMA: approved

    M09AX02
  11. strontium ranelate

    OSSEOR

    EMA: withdrawn

    M05BX03
  12. sucroferric oxyhydroxide

    VELPHORO Seqirus (Australia) Pty Ltd

    EMA: approved Β· TGA: approved

    V03AE05
  13. sufentanil

    DZUVEO

    EMA: approved Β· NMPA: clinical trials

    N01AH03
  14. sugemalimab

    CEJEMLY

    EMA: approved

    L01FF11
  15. sulesomab

    LEUKOSCAN

    EMA: withdrawn

    VO4D
  16. sulphur hexafluoride

    SONOVUE

    EMA: approved

    V08DA05
  17. sunitinib

    ARX-SUNITINIB Pfizer Australia Pty Ltd

    EMA: approved Β· TGA: approved

    L01EX01
  18. surufatinib

    SEVSURY

    EMA: application withdrawn Β· NMPA: clinical trials

    L01EX01
  19. susoctocog alfa

    OBIZUR

    EMA: approved

    B02
  20. sutimlimab

    ENJAYMO

    EMA: approved

    L04AJ04
  21. tabelecleucel

    EBVALLO

    EMA: approved

  22. tafasitamab

    MINJUVI

    EMA: approved

    L01FX12
  23. tagraxofusp

    ELZONRIS

    EMA: approved

    L01XX67
  24. talazoparib

    TALZENNA Pfizer Australia Pty Ltd

    EMA: approved Β· TGA: approved

    L01XK04

Frequently asked questions

What is the NovaPharmaNews drugs directory?

It is a searchable index of 4,797 pharmaceutical active ingredients and their marketed profiles β€” INN, brand names, US regulatory status, manufacturers, and cross-links to clinical pipeline and patent records.

Where does drug approval data come from?

Profiles combine FDA Drugs@FDA and Orange Book references, ClinicalTrials.gov pipeline links, and editorial enrichment. See our data sources page for attribution and update cadence. This directory is for professional reference, not medical advice.

How do I find a drug by brand name?

Use the search box on this page β€” it matches both INN (generic name) and slug. Brand names appear on each drug row and on the full drug profile page, with links to the originator company when available.